![]() ILMOFOSINE structure
|
Common Name | ILMOFOSINE | ||
---|---|---|---|---|
CAS Number | 83519-04-4 | Molecular Weight | 525.76500 | |
Density | N/A | Boiling Point | N/A | |
Molecular Formula | C26H56NO5PS | Melting Point | N/A | |
MSDS | Chinese USA | Flash Point | N/A | |
Symbol |
![]() GHS06 |
Signal Word | Danger |
Name | 3-(hexadecylthio)-2-(MethoxyMethyl)propyl 2-(triMethylaMMonio)ethyl phosphate |
---|
Molecular Formula | C26H56NO5PS |
---|---|
Molecular Weight | 525.76500 |
Exact Mass | 525.36200 |
PSA | 102.93000 |
LogP | 7.74150 |
CHEMICAL IDENTIFICATION
HEALTH HAZARD DATAACUTE TOXICITY DATA
MUTATION DATA
|
Symbol |
![]() GHS06 |
---|---|
Signal Word | Danger |
Hazard Statements | H301 |
Precautionary Statements | P301 + P310 |
Personal Protective Equipment | dust mask type N95 (US);Eyeshields;Faceshields;Gloves |
Hazard Codes | Xn: Harmful; |
Risk Phrases | 22 |
RIDADR | UN 2811 6.1/PG 3 |
RTECS | JH4758000 |
~% ILMOFOSINE CAS#:83519-04-4 |
Literature: Reddy, Kasireddy Chandraprakash; Byun, Hoe-Sup; Bittman, Robert Tetrahedron Letters, 1994 , vol. 35, # 17 p. 2679 - 2682 |
~% ILMOFOSINE CAS#:83519-04-4 |
Literature: Reddy, Kasireddy Chandraprakash; Byun, Hoe-Sup; Bittman, Robert Tetrahedron Letters, 1994 , vol. 35, # 17 p. 2679 - 2682 |
Phase I trial of ilmofosine as a 24 hour infusion weekly.
Invest. New Drugs 13(3) , 205-10, (1995) Ilmofosine, an ether lipid derivative of lysophosphatidylcholine has antineoplastic activity in vitro and in vivo. Maximum efficacy in preclinical models is associated with prolonged exposure to the d... |
|
A phase II trial of ilmofosine in non-small cell bronchogenic carcinoma.
Invest. New Drugs 14(2) , 219-22, (1996) We have conducted a study of ilmofosine (1-hexadecylthio; 2-methoxyethyl-rac-glycero-3-phosphocholine) in non-small cell bronchogenic carcinoma, using a schedule of continuous infusion for 5 days and ... |
|
Structure-function relationships of alkyl-lysophospholipid analogs in selective antitumor activity.
Lipids 28(6) , 511-6, (1993) This investigation was initiated in order to delineate the structure-function relationship of the anticancer alkyl-lysophospholipids and assess their degree of selective cytotoxicity toward neoplastic... |